Novo Nordisk A/S Sponsored ADR (NVO)
Exclusive: Novo Nordisk cuts Wegovy price by up to 33% in India, document shows
Danish drugmaker Novo Nordisk on Tuesday cut the price of its blockbuster weight-loss drug, Wegovy, by up to 33% in India, according to a document seen by Reuters.
Novo Nordisk: Buy This Bargain
Novo Nordisk A/S shares have declined sharply, but the company remains profitable with a positive long-term growth outlook and a strong cash position. NVO's decision to walk away from the Metsera, Inc. acquisition demonstrates disciplined capital allocation, with potential for organic growth, smaller deals, and shareholder returns. Despite slower growth due to competition and a maturing obesity drug market, NVO still posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Norway's sovereign wealth fund to abstain from Novo Nordisk board vote
Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk's extraordinary shareholders' meeting scheduled for November 14.
Novo Nordisk to sell weight loss drug Poviztra in India
Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country, the Indian firm said on Monday.
Novo Nordisk: Hold On Tightly As The Market Tests Your Faith
Novo Nordisk faces persistent investor skepticism due to competitive pressures from Eli Lilly and repeated downward guidance revisions. NVO's recent management changes and strategic revamp aim to restore credibility, but execution risks remain high amid stalled growth and market share losses. Despite losing a bidding war to Pfizer, NVO's capital discipline and strong profitability position it well for future opportunities, including the upcoming oral Wegovy launch.
Should You Buy Novo Nordisk After the Huge Investor Update?
Novo Nordisk (NVO 1.89%) is struggling with competition in its weight loss treatment business and is looking to make an acquisition to bolster its pipeline of drugs.
Trump administration reaches deal to lower prices of obesity and diabetes drugs
The Trump administration has announced agreements with pharmaceutical companies Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) to reduce the cost of GLP-1 medications used to treat obesity, diabetes, and related conditions. The initiative seeks to expand access and affordability for millions of Americans, including those covered by Medicare and Medicaid.
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call November 5, 2025 6:30 AM EST Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board David Moore - Executive VP of US Operations & Member of Management Board Martin Lange - EVP of R&D, Chief Scientific Officer and Member of the Management Board Karsten Knudsen - Executive VP, CFO & Member of the Management Board Conference Call Participants Carsten Madsen - Danske Bank A/S, Research Division Peter Verdult - BNP Paribas, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Novo Nordisk Q3: Why I'm Not Giving Up Yet
Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 2025 showed net sales up 15% at CER and operating profit up 21% excluding one-offs. Obesity Care, led by Wegovy, saw 41% sales growth at CER, and the upcoming Wegovy pill approval could significantly boost adoption and revenue.
Novo Nordisk says its head of manufacturing is stepping down
Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was stepping down.
Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations
Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027.
